MIST
Income statement / Annual
Last year (2025), Milestone Pharmaceuticals Inc's total revenue was $1.55 M,
and the percentage change from the previous year is not available.
In 2025, Milestone Pharmaceuticals Inc's net income was -$63.06 M.
See Milestone Pharmaceuticals Inc,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
| Period Ended |
12/31/2025 |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
| Operating Revenue |
$1.55 M |
$0.00 |
$1.00 M |
$5.00 M |
$15.00 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$114.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$10.00 K
|
$8.00 K
|
| Gross Profit |
$1.43 M
|
$0.00
|
$1.00 M
|
$5.00 M
|
$15.00 M
|
$0.00
|
$0.00
|
-$10.00 K
|
-$8.00 K
|
| Gross Profit Ratio |
0.93
|
0
|
1
|
1
|
1
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$18.11 M
|
$14.36 M
|
$31.05 M
|
$39.83 M
|
$38.67 M
|
$34.86 M
|
$42.38 M
|
$16.85 M
|
$5.64 M
|
| General & Administrative Expenses |
$17.27 M
|
$16.74 M
|
$15.93 M
|
$15.72 M
|
$12.40 M
|
$9.97 M
|
$6.73 M
|
$3.05 M
|
$1.50 M
|
| Selling & Marketing Expenses |
$0.00
|
$11.00 M
|
$15.11 M
|
$9.10 M
|
$7.00 M
|
$5.94 M
|
$8.89 M
|
$3.92 M
|
$1.13 M
|
| Selling, General & Administrative Expenses |
$17.27 M
|
$27.75 M
|
$31.05 M
|
$24.81 M
|
$19.40 M
|
$15.90 M
|
$15.62 M
|
$6.97 M
|
$2.63 M
|
| Other Expenses |
$28.54 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$55.00 K
|
-$115.00 K
|
$0.00
|
$0.00
|
| Operating Expenses |
$63.92 M
|
$42.10 M
|
$62.10 M
|
$64.64 M
|
$58.07 M
|
$50.71 M
|
$57.88 M
|
$23.82 M
|
$8.27 M
|
| Cost And Expenses |
$64.03 M
|
$42.10 M
|
$62.10 M
|
$64.64 M
|
$58.07 M
|
$50.71 M
|
$57.88 M
|
$23.82 M
|
$8.27 M
|
| Interest Income |
$2.92 M
|
$4.16 M
|
$3.97 M
|
$1.25 M
|
$220.00 K
|
$726.00 K
|
$2.60 M
|
$711.00 K
|
$186.00 K
|
| Interest Expense |
$3.84 M
|
-$3.58 M
|
$2.55 M
|
$0.00
|
$0.00
|
$726.00 K
|
$2.60 M
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$114.00 K
|
$105.00 K
|
$92.00 K
|
$89.00 K
|
$93.00 K
|
$97.00 K
|
$38.00 K
|
$10.00 K
|
$8.00 K
|
| EBITDA |
-$59.45 M |
-$37.83 M |
-$57.04 M |
-$58.30 M |
-$42.76 M |
-$50.61 M |
-$57.84 M |
-$23.36 M |
-$8.26 M |
| EBITDA Ratio |
-38.45
|
0
|
-57.04
|
-11.66
|
-2.85
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
-40.42
|
0
|
-61.1
|
-11.93
|
-2.87
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
-$918.00 K
|
$583.00 K
|
$1.41 M
|
$1.25 M
|
$220.00 K
|
$726.00 K
|
$2.60 M
|
$711.00 K
|
$186.00 K
|
| Income Before Tax |
-$63.40 M
|
-$41.52 M
|
-$59.69 M
|
-$58.39 M
|
-$42.85 M
|
-$49.98 M
|
$55.29 M
|
-$23.11 M
|
-$8.08 M
|
| Income Before Tax Ratio |
-41.01
|
0
|
-59.69
|
-11.68
|
-2.86
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
-$345.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$17.00 K
|
$56.00 K
|
$74.00 K
|
$4.00 K
|
| Net Income |
-$63.06 M
|
-$41.52 M
|
-$59.69 M
|
-$58.39 M
|
-$42.85 M
|
-$49.97 M
|
-$55.23 M
|
-$23.19 M
|
-$8.09 M
|
| Net Income Ratio |
-40.79
|
0
|
-59.69
|
-11.68
|
-2.86
|
0
|
0
|
0
|
0
|
| EPS |
-0.75 |
-0.67 |
-1.39 |
-1.35 |
-1.02 |
-1.7 |
-3.5 |
-0.98 |
-0.34 |
| EPS Diluted |
-0.75 |
-0.67 |
-1.39 |
-1.35 |
-1.02 |
-1.7 |
-3.5 |
-0.98 |
-0.34 |
| Weighted Average Shares Out |
$83.88 M
|
$62.21 M
|
$42.96 M
|
$42.45 M
|
$41.83 M
|
$29.34 M
|
$15.78 M
|
$23.65 M
|
$23.65 M
|
| Weighted Average Shares Out Diluted |
$83.88 M
|
$62.21 M
|
$42.96 M
|
$42.45 M
|
$41.83 M
|
$29.34 M
|
$15.78 M
|
$23.65 M
|
$23.65 M
|
| Link |
|
|
|
|
|
|
|
|
|
